Baricitinib Effective in JIA Subsets A phase 3 trial assessed a selective Janus kinase 1/2-inhibitor, baricitinib, in patients with juvenile idiopathic arthritis (JIA), demonstrating it's efficacy and safety compared to placebo. https://t.co/0CMzVCgsG8 https://t.co/NGE1pxsmcb